Arcticzymes Technologies ASA (AZT) - Net Assets
Based on the latest financial reports, Arcticzymes Technologies ASA (AZT) has net assets worth Nkr338.47 Million NOK (≈ $35.62 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr361.41 Million ≈ $38.03 Million USD) and total liabilities (Nkr22.94 Million ≈ $2.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Arcticzymes Technologies ASA to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr338.47 Million |
| % of Total Assets | 93.65% |
| Annual Growth Rate | 7.28% |
| 5-Year Change | 38.24% |
| 10-Year Change | 397.12% |
| Growth Volatility | 83.96 |
Arcticzymes Technologies ASA - Net Assets Trend (2002–2025)
This chart illustrates how Arcticzymes Technologies ASA's net assets have evolved over time, based on quarterly financial data. Also explore how large is Arcticzymes Technologies ASA's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Arcticzymes Technologies ASA (2002–2025)
The table below shows the annual net assets of Arcticzymes Technologies ASA from 2002 to 2025. For live valuation and market cap data, see Arcticzymes Technologies ASA market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr338.47 Million ≈ $35.62 Million |
+4.68% |
| 2024-12-31 | Nkr323.35 Million ≈ $34.03 Million |
+4.54% |
| 2023-12-31 | Nkr309.30 Million ≈ $32.55 Million |
+8.63% |
| 2022-12-31 | Nkr284.74 Million ≈ $29.96 Million |
+16.29% |
| 2021-12-31 | Nkr244.84 Million ≈ $25.76 Million |
+24.71% |
| 2020-12-31 | Nkr196.33 Million ≈ $20.66 Million |
+322.39% |
| 2019-12-31 | Nkr46.48 Million ≈ $4.89 Million |
-13.77% |
| 2018-12-31 | Nkr53.90 Million ≈ $5.67 Million |
+20.27% |
| 2017-12-31 | Nkr44.81 Million ≈ $4.72 Million |
-34.18% |
| 2016-12-31 | Nkr68.08 Million ≈ $7.16 Million |
-21.52% |
| 2015-12-31 | Nkr86.75 Million ≈ $9.13 Million |
-12.26% |
| 2014-12-31 | Nkr98.87 Million ≈ $10.40 Million |
+132.50% |
| 2013-12-31 | Nkr42.52 Million ≈ $4.47 Million |
+94.10% |
| 2012-12-31 | Nkr21.91 Million ≈ $2.31 Million |
-52.20% |
| 2011-12-31 | Nkr45.83 Million ≈ $4.82 Million |
+25.96% |
| 2010-12-31 | Nkr36.39 Million ≈ $3.83 Million |
-40.50% |
| 2009-12-31 | Nkr61.15 Million ≈ $6.44 Million |
-61.60% |
| 2008-12-31 | Nkr159.27 Million ≈ $16.76 Million |
-21.94% |
| 2007-12-31 | Nkr204.04 Million ≈ $21.47 Million |
+93.02% |
| 2006-12-31 | Nkr105.71 Million ≈ $11.12 Million |
-17.26% |
| 2005-12-31 | Nkr127.76 Million ≈ $13.44 Million |
+159.75% |
| 2004-12-31 | Nkr49.18 Million ≈ $5.18 Million |
-13.34% |
| 2003-12-31 | Nkr56.75 Million ≈ $5.97 Million |
-15.58% |
| 2002-12-31 | Nkr67.23 Million ≈ $7.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Arcticzymes Technologies ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2162600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr21.63 Million | 6.39% |
| Other Components | Nkr316.84 Million | 93.61% |
| Total Equity | Nkr338.47 Million | 100.00% |
Arcticzymes Technologies ASA Competitors by Market Cap
The table below lists competitors of Arcticzymes Technologies ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
51Talk Online Education Group
NYSE MKT:COE
|
$117.74 Million |
|
Codes Combine Co. Ltd
KQ:047770
|
$117.84 Million |
|
GoPro Inc
NASDAQ:GPRO
|
$117.86 Million |
|
Iljin Power Co. Ltd
KQ:094820
|
$117.88 Million |
|
Kc Cottrell
KO:119650
|
$117.68 Million |
|
Cantor Equity Partners, Inc. Class A Ordinary Shares
NASDAQ:CEP
|
$117.63 Million |
|
Chinyang Hold
KO:100250
|
$117.62 Million |
|
Genelux Corporation Common Stock
NASDAQ:GNLX
|
$117.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcticzymes Technologies ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 323,350,000 to 338,467,000, a change of 15,117,000 (4.7%).
- Net income of 9,881,000 contributed positively to equity growth.
- Other factors increased equity by 5,236,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr9.88 Million | +2.92% |
| Other Changes | Nkr5.24 Million | +1.55% |
| Total Change | Nkr- | 4.68% |
Book Value vs Market Value Analysis
This analysis compares Arcticzymes Technologies ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.84x to 3.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Nkr3.75 | Nkr21.90 | x |
| 2003-12-31 | Nkr3.16 | Nkr21.90 | x |
| 2004-12-31 | Nkr1.02 | Nkr21.90 | x |
| 2005-12-31 | Nkr6.92 | Nkr21.90 | x |
| 2006-12-31 | Nkr4.92 | Nkr21.90 | x |
| 2007-12-31 | Nkr8.76 | Nkr21.90 | x |
| 2008-12-31 | Nkr6.33 | Nkr21.90 | x |
| 2009-12-31 | Nkr2.40 | Nkr21.90 | x |
| 2010-12-31 | Nkr1.43 | Nkr21.90 | x |
| 2011-12-31 | Nkr1.53 | Nkr21.90 | x |
| 2012-12-31 | Nkr0.68 | Nkr21.90 | x |
| 2013-12-31 | Nkr1.07 | Nkr21.90 | x |
| 2014-12-31 | Nkr2.28 | Nkr21.90 | x |
| 2015-12-31 | Nkr1.94 | Nkr21.90 | x |
| 2016-12-31 | Nkr1.50 | Nkr21.90 | x |
| 2017-12-31 | Nkr0.98 | Nkr21.90 | x |
| 2018-12-31 | Nkr1.13 | Nkr21.90 | x |
| 2019-12-31 | Nkr0.93 | Nkr21.90 | x |
| 2020-12-31 | Nkr3.96 | Nkr21.90 | x |
| 2021-12-31 | Nkr4.84 | Nkr21.90 | x |
| 2022-12-31 | Nkr5.63 | Nkr21.90 | x |
| 2023-12-31 | Nkr6.08 | Nkr21.90 | x |
| 2024-12-31 | Nkr6.33 | Nkr21.90 | x |
| 2025-12-31 | Nkr6.63 | Nkr21.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcticzymes Technologies ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.77%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.07x
- Recent ROE (2.92%) is above the historical average (-27.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -0.96% | -9.22% | 0.91x | 0.11x | Nkr-7.37 Million |
| 2003 | -17.33% | -13.60% | 1.10x | 1.15x | Nkr-15.51 Million |
| 2005 | -12.09% | -22.05% | 0.50x | 1.10x | Nkr-28.22 Million |
| 2006 | -25.21% | -36.53% | 0.59x | 1.17x | Nkr-37.23 Million |
| 2007 | -9.15% | -25.49% | 0.33x | 1.08x | Nkr-39.07 Million |
| 2008 | -32.76% | -100.92% | 0.28x | 1.18x | Nkr-68.11 Million |
| 2009 | -162.49% | -412.76% | 0.26x | 1.51x | Nkr-105.49 Million |
| 2010 | -78.44% | -110.16% | 0.38x | 1.90x | Nkr-32.18 Million |
| 2011 | -45.52% | -87.28% | 0.41x | 1.28x | Nkr-24.52 Million |
| 2012 | -117.33% | -113.24% | 0.67x | 1.56x | Nkr-26.39 Million |
| 2013 | -54.91% | -103.53% | 0.41x | 1.29x | Nkr-27.06 Million |
| 2014 | -22.34% | -66.59% | 0.30x | 1.13x | Nkr-31.84 Million |
| 2015 | -20.11% | -32.55% | 0.53x | 1.17x | Nkr-25.97 Million |
| 2016 | -30.34% | -28.48% | 0.84x | 1.27x | Nkr-27.23 Million |
| 2017 | -56.55% | -37.40% | 1.08x | 1.40x | Nkr-29.35 Million |
| 2018 | -26.38% | -20.95% | 0.98x | 1.28x | Nkr-19.29 Million |
| 2019 | -14.15% | -8.27% | 1.00x | 1.72x | Nkr-10.90 Million |
| 2020 | 42.76% | 88.95% | 0.42x | 1.14x | Nkr63.68 Million |
| 2021 | 18.94% | 36.24% | 0.45x | 1.16x | Nkr21.90 Million |
| 2022 | 11.54% | 23.99% | 0.43x | 1.12x | Nkr4.39 Million |
| 2023 | 6.28% | 16.33% | 0.35x | 1.10x | Nkr-11.50 Million |
| 2024 | 2.62% | 8.12% | 0.30x | 1.06x | Nkr-23.87 Million |
| 2025 | 2.92% | 8.77% | 0.31x | 1.07x | Nkr-23.97 Million |
Industry Comparison
This section compares Arcticzymes Technologies ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $103,615,372
- Average return on equity (ROE) among peers: -91.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcticzymes Technologies ASA (AZT) | Nkr338.47 Million | -0.96% | 0.07x | $117.69 Million |
| Bergenbio ASA (BGBIO) | $12.05 Million | 0.00% | 0.48x | $7.75 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $146.68 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $9.59 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $80.92 Million |
| Nykode Therapeutics ASA (NYKD) | $242.56 Million | -49.57% | 0.21x | $110.82 Million |
| Oncoinvent ASA (ONCIN) | $146.33 Million | -105.98% | 0.40x | $23.00 Million |
| PCI Biotech Holding ASA (PCIB) | $339.95 Million | -10.23% | 0.05x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $76.22 Million | -49.08% | 0.15x | $28.83 Million |
| Thor Medical ASA (TRMED) | $63.84 Million | -487.52% | 0.72x | $164.94 Million |
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more